ABSTRACT
The Amplatzer® Septal Occluder (ASO) (AGA Medical Corporation, Plymouth, MN) is a self-expanding and self-centering occlusion device consisting of a Nitinol meshwork forming a left atrial disc, a self-centering stent, and a right atrial disc.1 The ASO was the first device approved by the US Food and Drug Administration (FDA) for percutaneous closure of secundum atrial septal defects (ASDs). Due to its ease of transcatheter deployment and the effectiveness of shunt closure it has gained widespread acceptance among interventionalists. However, complications, both acute and chronic occur, which will be reviewed in this chapter.
